J Neurol Surg B Skull Base 2022; 83(04): 350-358
DOI: 10.1055/s-0041-1736590
Original Article

Surgical Management of Rhabdomyosarcoma of the Nasal Cavity and Paranasal Sinuses: Analysis of Operative Indications, Settings, and Outcomes

Lulia A. Kana#
1   Department of Otolaryngology—Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, United States
,
Joshua D. Smith#
1   Department of Otolaryngology—Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, United States
,
Emily L. Bellile
2   Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, United States
,
Rashmi Chugh
3   Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, United States
,
Erin L. McKean
1   Department of Otolaryngology—Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, United States
4   Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan, United States
› Author Affiliations
Funding None.

Abstract

Objectives The role of surgery in management of sinonasal rhabdomyosarcoma (SNRMS) has traditionally been limited, owing to anatomic and technological challenges and the established role of systemic therapy. Herein, we report our institutional experience with surgical management of SNRMS, with a particular focus on operative approaches, extent and outcomes.

Design This study is a retrospective cohort study.

Setting This study was conducted at a single-institution, academic center.

Participants Patients of any age with histologically confirmed RMS of the nasal cavity, maxillary, ethmoid, frontal, or sphenoid sinus, nasolacrimal duct, or nasopharynx presenting between 1994 and 2020 were included in this study.

Main Outcome Measures Demographics, tumor characteristics, operative settings, complications and recurrence, and survival outcomes were the primary outcomes of this study.

Results Our study cohort comprised of 29 patients (mean [range] age: 27.0 [3.1–65.7], n = 12 [41%] female). Tumors of the nasal cavity (n = 10, 35%) and ethmoid sinuses (n = 10, 35%) and those with alveolar histology (n = 21, 72%) predominated. Patients who had surgery as part of their treatment (n = 13, 45%) had improved distant metastasis-free survival (DMFS) overall (hazard ratio [HR]: 0.32, 95% CI: 0.11, 0.98, p = 0.05) as compared with those who did not have surgery. Surgical approaches included open (n = 7), endoscopic (n = 4), and combined (n = 2). Eight of these 13 patients (62%) had an R0 resection. Additionally, surgical salvage of recurrent disease was employed in five patients (17%).

Conclusion SNRMS is an aggressive malignancy with a high rate of recurrence and spread requiring a multidisciplinary approach for optimal outcomes. Our data supports an expanding role for surgery for SNRMS given its feasibility, tolerability, and potential to improve outcomes.

Note

This work was presented in virtual format at the North American Skull Base Society (NASBS) 2021 Virtual Symposium.


# Equal Contribution.




Publication History

Received: 19 April 2021

Accepted: 22 September 2021

Article published online:
08 November 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Turner JH, Richmon JD. Head and neck rhabdomyosarcoma: a critical analysis of population-based incidence and survival data. Otolaryngol Head Neck Surg 2011; 145 (06) 967-973
  • 2 Rodeberg DA, Paidas CN, Lobe TL. et al. Surgical principles for children/adolescents with newly diagnosed rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group. Sarcoma 2002; 6 (04) 111-122
  • 3 Raney RB, Meza J, Anderson JR. et al. Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol 2002; 38 (01) 22-32
  • 4 Daya H, Chan HSL, Sirkin W, Forte V. Pediatric rhabdomyosarcoma of the head and neck: is there a place for surgical management?. Arch Otolaryngol Head Neck Surg 2000; 126 (04) 468-472
  • 5 Stevens MC. Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol 2005; 6 (02) 77-84
  • 6 Gillespie MB, Marshall DT, Day TA, Mitchell AO, White DR, Barredo JC. Pediatric rhabdomyosarcoma of the head and neck. Curr Treat Options Oncol 2006; 7 (01) 13-22
  • 7 Maurer HM, Beltangady M, Gehan EA. et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988; 61 (02) 209-220
  • 8 Crist WM, Anderson JR, Meza JL. et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001; 19 (12) 3091-3102
  • 9 Fyrmpas G, Wurm J, Athanassiadou F. et al. Management of paediatric sinonasal rhabdomyosarcoma. J Laryngol Otol 2009; 123 (09) 990-996
  • 10 Gradoni P, Giordano D, ORetti G, Fantoni M, Ferri T. The role of surgery in children with head and neck rhabdomyosarcoma and Ewing's sarcoma. Surg Oncol 2010; 19: 103-109
  • 11 Cecchetto G, Bisogno G, De Corti F. et al; Italian Cooperative Group. Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children?: the experience of the Italian Cooperative Group studies. Cancer 2007; 110 (11) 2561-2567
  • 12 Dasgupta R, Rodeberg DA. Update on rhabdomyosarcoma. Semin Pediatr Surg 2012; 21 (01) 68-78
  • 13 Rodeberg DA, Wharam MD, Lyden ER. et al. Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Int J Cancer 2015; 137 (01) 204-211
  • 14 Wertz A, Tillman BN, Brinkmeier JV. et al. Minimally invasive approach for resection of parameningeal rhabdomyosarcoma. J Neurol Surg B Skull Base 2017; 78 (03) 210-214
  • 15 Hanauer DA, Barnholtz-Sloan JS, Beno MF. et al. Electronic medical record search engine (EMERSE): an information retrieval tool for supporting cancer research. JCO Clin Cancer Inform 2020; 4: 454-463
  • 16 Lawrence Jr. W, Gehan EA, Hays DM, Beltangady M, Maurer HM. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol 1987; 5 (01) 46-54
  • 17 Breneman JC, Lyden E, Pappo AS. et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma–a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003; 21 (01) 78-84
  • 18 Sanghvi S, Misra P, Patel NR, Kalyoussef E, Baredes S, Eloy JA. Incidence trends and long-term survival analysis of sinonasal rhabdomyosarcoma. Am J Otolaryngol 2013; 34 (06) 682-689
  • 19 Stepan K, Konuthula N, Khan M. et al. Outcomes in adult sinonasal rhabdomyosarcoma. Otolaryngol Head Neck Surg 2017; 157 (01) 135-141
  • 20 Unsal AA, Chung SY, Unsal AB, Baredes S, Eloy JA. A population-based analysis of survival for sinonasal rhabdomyosarcoma. Otolaryngol Head Neck Surg 2017; 157 (01) 142-149
  • 21 Li W, Lu H, Wang D. Therapeutic outcome and prognostic factors in sinonasal rhabdomyosarcoma: a single-institution case series. J Cancer Res Clin Oncol 2019; 145 (11) 2793-2802
  • 22 Siddiqui SH, Siddiqui E, Bavier RD. et al. Clinicopathologic traits and prognostic factors associated with pediatric sinonasal rhabdomyosarcoma. Int Forum Allergy Rhinol 2019; 9 (04) 363-369
  • 23 Sercarz JA, Mark RJ, Nasri S, Wang MB, Tran LM. Pediatric rhabdomyosarcoma of the head and neck. Int J Pediatr Otorhinolaryngol 1995; 31 (01) 15-22
  • 24 Paulino AC, Bauman N, Simon JH, Nguyen TX, Ritchie JM, Tannous R. Local control of parameningeal rhabdomyosarcoma: outcomes in non-complete responders to chemoradiation. Med Pediatr Oncol 2003; 41 (02) 118-122